Prelude Capital Management, LLC Pacira Bio Sciences, Inc. Transaction History
Prelude Capital Management, LLC
- $1.5 Billion
- Q4 2024
A detailed history of Prelude Capital Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 19,535 shares of PCRX stock, worth $469,816. This represents 0.02% of its overall portfolio holdings.
Number of Shares
19,535
Previous 21,935
10.94%
Holding current value
$469,816
Previous $330,000
11.52%
% of portfolio
0.02%
Previous 0.02%
Shares
16 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$193 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$127 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$78.5 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$54.3 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$47.9 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.1B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...